Dear Editor: Atypical long-acting injectable (LAI) antipsychotics may improve treatment options for patients with serious mental illnesses, such as schizophrenia and bipolar disorder.[1] A systematic review of 1,700 outpatients from
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
Innov Clin Neurosci. 2015;12(5–6 Suppl B):3–19. CNS Drug Compounds/Therapies/Devices Long-acting injectable antipsychotics (LAIs) in outpatient treatment of DMS-IV-R schizophrenia Presenters: Bellnier T, Patil K, Ortega T, Seeger G Affiliations: SUNY
by Rajshekhar Bipeta, MBBS, DPM, DNB (psych); Srinivasa SRR Yerramilli, MD (psych); Ashok Reddy Karredla, MD (psych); and Srinath Gopinath, MBBS, DPM Dr. Bipeta is a consultant psychiatrist from Rajasri
by Murali K. Kolikonda, MD; Suneela Cherlopalle, MD; Manasa Enja, MD; and Steven Lippmann, MD Drs. Kolikonda, Cherlopalle, Enja, and Lippmann are with the University of Louisville School of Medicine,
by Mitali Wadekar, MD; Anil Sharma, MD, MBA; and Gina Battaglia, PhD Drs. Wadekar and Sharma are with IRB Company, Inc., Buena Park, California, and Dr. Bittaglia is an independent
by Randy A. Sansone, MD, and Lori A. Sansone, MD R. Sansone is a professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine
by Ann McNary, JD Ms. McNary is Senior Risk Manager, Professional Risk Management Services, Arlington, Virginia. Innov Clin Neurosci. 2015;12(3–4):37–40.
Innov Clin Neurosci. 2015;12(3–4):11–13.
by Jared W. Young, PhD; William Z. Potter, MD, PhD; Steve Riley, PharmD, PhD; Geert J. Groeneveld, MD, PhD; Bruce J. Kinon, MD; Mike F. Egan, MD; and Douglas E.
by Steven T. Szabo, MD, PhD; Bruce J. Kinon, MD; Stephen K. Brannan, MD; Andrew K. Krystal, MD, MSc; Joop M A van Gerven, MD, PhD; Atul Mahableshwarkar, MD; and
by Harald Murck, MD, PhD; Thomas Laughren, MD; Femke Lamers, PhD; Rosalind Picard, ScD; Sebastian Walther, MD; Donald Goff, MD; and Stephen Sainati, MD, PhD Dr. Murck is with Acorda
by Shahid Ali, MD; Shagufta Jabeen, MD; and Farzana Alam, MD Dr. Ali is Associate Professor of Clinical Psychiatry, Meharry Medical College, Nashville, Tennessee; Dr. Jabeen is Adjunct Associate Clinical
by Radhika Bawa, MD, and Jonathan R. Scarff, MD Dr. Bawa is with Lehman College, the City University of New York, Bronx, New York; and Dr. Scarff is with Veterans
by Rocco S. Calabrò, MD, PhD; Placido Bramanti, MD; Annalisa Baglieri, PsyD, PhD; Francesco Corallo, PsyD; Rosaria De Luca, MSc, PhD; Simona De Salvo, MSc; Silvia Marino, MD, PhD All
by Jae Lee, DO; Puneet Narang, MD; Manasa Enja, MD; and Steven Lippmann, MD Dr. Lee is resident physician at Hennepin-Regions Psychiatry Program, Minneapolis-St. Paul, Minnesota; Dr. Narang is staff
by Randy A. Sansone, MD, and Lori A. Sansone, MD R. Sansone is a professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine
